Author: healthylife7

Although the U.S. experiences seasonal cyclospora outbreaks, this year has seen thousands of CDC-confirmed cases across multiple states, far exceeding typical trends

With generic semaglutide injections now approved in Canada, a new study is revealing interest in weight loss medication is on the rise. 

The 16th BRICS Health Ministers’ meeting.(Photo | X / @MoHFW_INDIA) Updated on: 23 Jul 2026, 5:05 pm

You use your eyes all day—but are you taking care of them?From long hours on screens to time spent in the sun, everyday habits can quietly affect your vision. But protecting your eyes doesn’t have to be complicated.Eric J. Rothchild, MD, an ophthalmologist at the John A. Moran Eye Center, shares six simple things you…

A Seattle-area raccoon with a shortened spine has become one of the internet’s most celebrated animals. Videos of Jimothy waddling through neighborhoods, balancing on backyard fences, and going about his nightly routine have gained millions of views. His popularity makes sense: He’s endearing and easy to recognize with his unique body shape. But what if…

For more than a decade, GLP-1 treatment for weight loss has required a weekly injection with a pre-filled pen that needed to be stored in the fridge. This acted as a barrier to entry for many potential patients who may be needle-averse or would struggle to stick to the strict storage and administration routine

DVIDS – Video – JMSDF conducts missile live-fire during RIMPAC 2026 sinking exercise

As U.S. home prices reach historic highs and proposed cuts to the Supplemental Nutrition Program (SNAP) are underway, the health of low-income rural residents is becoming a cause for concern.  Meeting nutritional needs is already a challenge in many rural areas, which tend to have higher food prices, less variety, and lower quality fresh meat…

Vote from advisory group – whose members include people linked to peptides industry – likely to embolden RFK Jr

Investing.com — Eli Lilly announced Thursday it will file for approval of its next-generation obesity drug retatrutide in the first quarter of 2027, pushing back from an earlier timeline that targeted this year. The pharmaceutical company said it needs additional time to collect and verify manufacturing and quality-control data required by regulators